

From Stardust..to Sun



Dilip Shanghavi: 1983: INR 10,000: Vapi



Family business: Pharmacy: psychatric drug

The Case Solutions.com





45+ Manufacturing sites



150 + markets served




30,000 + employees



US\$ 20bn + worth of Revenue

2000+ products



India's top pharma company

Values & Strategies



Gobal leader in Generic and OTC market in next 10 years



Provide affordable medicines with stringent quality to all



Maximise the use of modern science and harnest best from the nature



"If you can't make it... buy it"



Strong focus on Exports (esp. USA) and R&D

SUN'S SWOT

Strength

- · Strong foothold in emerging market
- · Highest number of USFDA
- · Strong Sales force of 12000+
- · Strong Brand presence in India and US
- Extensive product catalogue due to successful acquisitions of Taro and Ranabaxy
- Independent and wholly owned research wing Sun Pharma Advanced Research Company
- · Ability to launch products consistently

Oppurtunities

- Ranbaxy's lucrative generic and OTC portfolio
- Further acquisitions to expand API market share
- · Contract Manufacturing
- · Relaxation of DPCO
- Animal Drugs segment

The Case Solutions.com

Weakness

- Lower profit margins
- Limited presence in merging markets of Africa and Asia as well as certain major markets of Europe
- Slim portfolio in OTC segment

Threats

- Continues loses made by Caraco Pharma in USA. Acquired by Sunpharma to compete with Pfizer
- Stiff Regulatory norms in both of its major market
- · Tewa-Actavis merger

Nurturing Idea's



R&D --> 1000Cr



200000 sq.ft facility for product development



2000 + research scientists



408 bed clinical testing facility for stage 1 testing



USFDA level New Chemical Entity

TheCaseSolutions



The Seeds....

"We are going to focus on our portfoilio approach. We are going to create some megabrands...and turn some smaller brands big."

"We are constantly looking out for new opportunities to expand our portfolio. The new product must fit into our business strategy and should be as useful for our customers as profitable it would be to us.

 Mr. Subodh Marwah
(VP and Global Head of Consumer Healthcare Division)

Volini 360

- OTC since 2007
- Tropical Analgesic: 2011 in Spray
- Zandu > Iodex > Volini [1]
- Pioneer in Diclofenac based gel and Spay SKU [2]
- Leader in spray segment [3]

From Sapling to Tree

- Push product, innovation
- ldea in 2014, consultation from a team of physios
- Exact pain point is tough to find during an injury and hence 360
- Dedicated testing laboratory at Baroda
- Better absorption of Diclofenac in blood and easy to use spray nozzle
- Tough competition from Appolo Pharmacy (Relispray)